TY - JOUR
T1 - The Cell Cycle Checkpoint Gene, RAD17 rs1045051, Is Associated with Prostate Cancer Risk
AU - Sun, Jingkai
AU - Lin, Wenfeng
AU - Wang, Qixu
AU - Sakai, Akiko
AU - Xue, Ruizhi
AU - Watanabe, Masami
AU - Liu, Chunxiao
AU - Sadahira, Takuya
AU - Nasu, Yasutomo
AU - Xu, Abai
AU - Huang, Peng
N1 - Funding Information:
Acknowledgments. This research was funded by the Ministry of Education, Culture, Sports, Science and Technology of Japan (grant no. 17K11138) and the Science and Technology Planning Project of Guangdong Province (grant no. 2016A020215109).
Publisher Copyright:
© 2021 by Okayama University Medical School
PY - 2021
Y1 - 2021
N2 - Human RAD17, as an agonist of checkpoint signaling, plays an essential role in mediating DNA damage. This hospital-based case-control study aimed to explore the association between RAD17 rs1045051, a missense single nucleotide polymorphism (SNP), and prostate cancer risk. Subjects were 358 prostate cancer patients and 314 cancer-free urology patients undergoing treatment at the Zhujiang Hospital of Southern Medical University in China. RAD17 gene polymorphism rs1045051 was evaluated by the SNaPshot method. Compared with the RAD17 gene polymorphism rs1045051 AA genotype, there was a higher risk of prostate cancer for the CC genotype (adjusted odds ratio [AOR]=1.731, 95% confidence interval [95%CI]=1.031−2.908, p=0.038). Compared with the A allele, the C allele was significantly associated with the disease status (AOR=1.302, 95%CI=1.037−1.634, p=0.023). All these findings indicate that in the SNP rs1045051, both the CC genotype and C allele may have a substantial influence on the prostate cancer risk.
AB - Human RAD17, as an agonist of checkpoint signaling, plays an essential role in mediating DNA damage. This hospital-based case-control study aimed to explore the association between RAD17 rs1045051, a missense single nucleotide polymorphism (SNP), and prostate cancer risk. Subjects were 358 prostate cancer patients and 314 cancer-free urology patients undergoing treatment at the Zhujiang Hospital of Southern Medical University in China. RAD17 gene polymorphism rs1045051 was evaluated by the SNaPshot method. Compared with the RAD17 gene polymorphism rs1045051 AA genotype, there was a higher risk of prostate cancer for the CC genotype (adjusted odds ratio [AOR]=1.731, 95% confidence interval [95%CI]=1.031−2.908, p=0.038). Compared with the A allele, the C allele was significantly associated with the disease status (AOR=1.302, 95%CI=1.037−1.634, p=0.023). All these findings indicate that in the SNP rs1045051, both the CC genotype and C allele may have a substantial influence on the prostate cancer risk.
KW - RAD17
KW - cell cycle checkpoint
KW - prostate cancer
KW - rs1045051
KW - single-nucleotide polymorphisms
UR - http://www.scopus.com/inward/record.url?scp=85115261004&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115261004&partnerID=8YFLogxK
M3 - Article
C2 - 34511607
AN - SCOPUS:85115261004
SN - 0386-300X
VL - 75
SP - 415
EP - 421
JO - Acta Medica Okayama
JF - Acta Medica Okayama
IS - 4
ER -
